Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001
Feb 17, 2024 - Patience will be rewarded with these stocks.
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/02/bristol-myers-squibb-bmy-q4-2023-earnings-call-tra/?source=iedfolrf0000001
Feb 02, 2024 - BMY earnings call for the period ending December 31, 2023.
0
Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb
https://www.zacks.com/commentary/2200541/top-stock-reports-for-microsoft-booking-holdings-bristol-myers-squibb?cid=CS-ZC-FT-research_daily-2200541
Dec 20, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).
0
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667
Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
0
Company News for Dec 26, 2023
https://www.zacks.com/stock/news/2202100/company-news-for-dec-26-2023?cid=CS-ZC-FT-corporate_summary-2202100
Dec 26, 2023 - Companies In The Articles: KRTX, BMY, NKE, TCEHY, RKLB
0
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
https://www.zacks.com/stock/news/2202691/bristol-myers-bmy-to-buy-cancer-drug-maker-rayzebio-for-4-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202691
Dec 27, 2023 - Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
0
Company News for Dec 27, 2023
https://www.zacks.com/stock/news/2202486/company-news-for-dec-27-2023?cid=CS-ZC-FT-corporate_summary-2202486
Dec 27, 2023 - Companies In The Article Are: INTC,RYZB,BMY,NIO,MANU
0
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052
Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
0
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
https://www.zacks.com/stock/news/2207159/exelixis-exel-posts-preliminary-2023-results-to-cut-13-jobs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207159
Jan 08, 2024 - Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
0
Page 1>